Cargando…

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome

KEY POINTS: Hepatorenal syndrome type 1 (HRS-1) is an often fatal, but potentially reversible, kidney failure in patients with decompensated cirrhosis. Treatment with terlipressin in patients with HRS-1 is associated with a reduction in the need for RRT. BACKGROUND: Hepatorenal syndrome type 1 (HRS-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Velez, Juan Carlos Q., Wong, Florence, Reddy, K. Rajender, Sanyal, Arun J., Vargas, Hugo E., Curry, Michael P., Gonzalez, Stevan A., Pappas, S. Chris, Jamil, Khurram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Nephrology 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482068/ https://www.ncbi.nlm.nih.gov/pubmed/37143199 http://dx.doi.org/10.34067/KID.0000000000000132

Ejemplares similares

Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure
por: Wong, Florence, et al.
Publicado: (2022)

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies
por: Curry, Michael P., et al.
Publicado: (2023)

Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome
por: Wong, Florence, et al.
Publicado: (2019)

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies
por: Sanyal, A. J., et al.
Publicado: (2017)

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial
por: Karvellas, Constantine J., et al.
Publicado: (2023)

Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome
por: Moore, Kevin, et al.
Publicado: (2020)

Hepatorenal syndrome:Response to terlipressin and albumin and its determinants
por: Sarwar, Shahid, et al.
Publicado: (2016)

Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT
por: Belcher, Justin M.
Publicado: (2023)

Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile
por: Ayyad, Ahlam, et al.
Publicado: (2023)

In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V(1) and V(2)
por: Jamil, Khurram, et al.
Publicado: (2017)

An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome
por: Bui, Thi Ngoc Nhieu, et al.
Publicado: (2020)

Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis
por: Wang, Haiqing, et al.
Publicado: (2018)

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome
por: Kim, Hae Rim, et al.
Publicado: (2013)

Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome
por: Chiang, Chi-Wen, et al.
Publicado: (2019)

Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials
por: Mohamed, Mohamed M G, et al.
Publicado: (2021)

Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis
por: Hiremath, Sharanabasayyaswamy B., et al.
Publicado: (2013)

Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
por: Nassar Junior, Antonio Paulo, et al.
Publicado: (2014)

Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?
por: Altun, Reskan, et al.
Publicado: (2015)

The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin
por: Flamm, Steven L., et al.
Publicado: (2021)

Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function
por: Huang, Xingyue, et al.
Publicado: (2023)

Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion
por: Weinberg, Ethan, et al.
Publicado: (2023)

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence
por: Bai, Zhaohui, et al.
Publicado: (2020)

Terlipressin-Induced Skin Necrosis While Managing Hepatorenal Syndrome: A Rare Case Report From North India
por: Sudan, Sourav, et al.
Publicado: (2023)

Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study
por: Kulkarni, Anand V., et al.
Publicado: (2022)

A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug
por: Thangaraj, Santhosh Raja, et al.
Publicado: (2023)

The Hepatorenal Syndrome Patient Pathway: Retrospective Analysis of Electronic Health Records
por: Jamil, Khurram, et al.
Publicado: (2022)

Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome
por: Abdel-Razik, Ahmed, et al.
Publicado: (2020)

Terlipressin or Europressin?
por: Leone, Marc
Publicado: (2009)

The haemodynamic effects of the perioperative terlipressin infusion in living donor liver transplantation: A randomised controlled study
por: Ibrahim, Nagwa, et al.
Publicado: (2015)

Terlipressin-induced hyponatraemia
por: Gray, R, et al.
Publicado: (2014)

Management of hepatorenal syndrome in liver cirrhosis: a recent update
por: Bera, Chinmay, et al.
Publicado: (2022)

Terlipressin‐induced foot ischemia
por: Ata, Fateen, et al.
Publicado: (2020)

Prognostic value of the dynamic hepatorenal function on intermediate‐term mortality in TAVI patients with survival to discharge
por: Yao, Yijun, et al.
Publicado: (2022)

Rebound hypotension following terlipressin bolus infusion can be prevented by continuous low-dose infusion of terlipressin
por: Lange, M, et al.
Publicado: (2007)

Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding
por: Zhang, Jingqiao, et al.
Publicado: (2020)

Ramipril poisoning rescued by naloxone and terlipressin
por: Samanta, Samanta, et al.
Publicado: (2014)

Vasopressin and terlipressin in adult vasodilatory shock
por: Polito, Angelo, et al.
Publicado: (2012)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

Hepatorenal Syndrome
por: Kiser, Tyree H.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_55pfroujv60cj37mstl1r56s2t